KCT0007722已完成未知
A Double-blind, Randomized, Placebo-controlled Intervention Study of the Efficacy and Safety of Submerged culture of Ceriporia Iacerata mycelium in patients with impaired fasting glucose intolerance or mild type 2 diabetes subjects
Fugenbio0 个研究点目标入组 72 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 75(Year)（—）
- 性别
- All
入选标准
- •1. Men between the ages of 20 and under 75 and non-lactating women with no possibility of pregnancy, except for the illiterate.
- •2. Subjects with a fasting blood sugar of 100 mg/dL or more and less than 140 mg/dL and HbA1c 7.0% or less, not taking diabetes medication
- •3. Subjects with a fasting blood sugar of less than 110 mg/dL or HbA1c 6.5% 7.0%
- •4. A person who voluntarily decides to participate and agrees in writing to abide by the precautions after hearing and fully understanding the detailed explanation of this human application test
排除标准
- •1. Subjects with adverse reactions such as allergies when taking medicines or health functional foods
- •2. Subjects with hypersensitivity to or a history of mushrooms
- •3. Gastrointestinal disorders that may affect the absorption of test products for human application
- •(Example: Crohn's disease) or gastrointestinal surgery (however, simple appendectomy or
- •Those with a history of hernia surgery)
- •4. Those who show the following results in a diagnostic medical test - AST, ALT > 2 times the upper limit of the normal range - Other significant diagnostic test findings
- •5. Those with the following clinically significant diseases
- •Diabetics taking blood sugar lowering drugs or insulin, uncontrolled
- •Hypertensive patients (140/90 or higher), blood LDL-cholesterol 160 or higher
- •factor, thyroid dysfunction patients, depression, schizophrenia, alcoholism
- •Patients with mental disorders such as heart disease, drug addiction, heart failure, angina pectoris, myocardial infarction, etc.
- •Cardiovascular disease, acute and chronic liver disease (chronic type B, chronic type C)
- •Hepatitis, various liver cirrhosis, liver cancer, etc.)
- •6. Obesity drugs, antidepressants, contraceptives, oral steroids within the last 1 month
- •Lloyd, female hormones, thyroid hormones, etc. have been taken or tested
- •Drugs that affect the absorption, metabolism, or excretion of food or to reduce blood sugar
- •Subjects with experience taking drugs that may affect
- •7. Pregnant and lactating women
- •8. Those who participated in other human application tests within 1 month before the first intake date
- •9. In the opinion of the person in charge of testing for human application, it is necessary to follow the
- •Subjects judged to be unsuitable or otherwise judged to be unsuitable by the physician.
研究者
相似试验
尚未招募
不适用
A Double-blind, Randomized, Placebo-controlled Intervention Study of the Efficacy and Safety of ID1216 in the Overweight SubjectKCT0000836Ildong pharmaceutical80
已完成
不适用
A Randomized, Double-blind, Placebo-controlled Intervention Study to evaluate the Efficacy and Safety of Barley Sprout” Extraction BS-1 in Healthy Volunteer with high cholesterolKCT0003434Kyung Hee University Hospital78
已完成
不适用
A study to evaluate the efficacy and safety of Investigational Product SLEPOVIN in patients with InsomniaCTRI/2019/05/019431BigBrother Nutra Care Pvt Ltd50
已完成
3 期
A double-blind, randomised, placebo-controlled interventional study to evaluate the effect of orally-dosed herbal extract, Testofen (Trigonella foenum-graecum) on muscle strength, endurance and body composition in men aged between 25 and 45 years.Body compositionMuscle StrengthPhysical StaminaMuscle RecoveryAlternative and Complementary Medicine - Herbal remediesPhysical Medicine / Rehabilitation - Other physical medicine / rehabilitationACTRN12616000938404Integrated Health Global Pty Ltd120
已完成
3 期
A double-blind, randomised, placebo-controlled interventional study to evaluate the effect of orally-dosed Almega PL on cardio-metabolic parameters and inflammatory markers in men and women.Cardio-metabolic paramentersCardiovascular - Coronary heart diseaseMetabolic and Endocrine - Other metabolic disordersACTRN12618000275268RDC Global Pty Ltd122